[February 27, 2017]

Global Biosimilar Insulin Market Opportunity & Clinical Insight Outlook 2022 - Research and Markets

Research and Markets has announced the addition of the "Global Biosimilar Insulin Market Opportunity & Clinical Insight Outlook 2022" report to their offering.

Global Biosimilar Insulin Market Opportunity & Clinical Insight Outlook 2022 report gives comprehensive insight on clinical and non-clinical issues involved with growth of global biosimilar insulin market.

This report analyzes various aspects like rationale design of insulin molecule, mechanism of insulin in diabetes, engineering of synthetic insulin, global aspects of biosimilar insulins along with market overview, biosimilar insulin clinical pipeline insight and future trends for the development of biosimilar insulin market.

The consequence of recent technological innovations, new regulations in the biopharmaceutical industry, and cost concerns, the idea of biosimilars has gathered attention towards them and their potential future market. In fact, efforts are already underway to develop a new class of follow-on biologics named biobetters or biosuperiors, which go beyond mimicking the original biologic to provide improvements through chages in chemistry, alteration in the formulation, and innovative delivery.

The potential of insulin biosimilars like Basaglar is huge in the upcoming future, the demand will significantly grow in developed market as the countries including US, Europe and Japan have shown a great enthusiasm towards biosimilar products especially Europe. The developed market somehow, with the exception of the United States, has represented the greatest biosimilars presence today. Most biosimilars manufacturers have been and remain focused on the developed markets whether it is for their historic and current opportunities (EU) or for their future market potential (United States, Japan).

Key Topics Covered:

1. Prologue to Insulin Biosimilars

2. Rationale Design of Insulin Molecule

3. Mechanism of Insulin in Diabetics

4. Engineering of Synthetic Insulin

5. Insulinotherapeutics in Diabetes

6. Global Economic Aspects of Insulin

7. Global Economic Cost of Diabetes

8. Global Aspects of Biosimilar Insulins

9. Global Biosimilar Insulin Market Overview

10. Global Biosimilar Insulin Clinical Pipeline Insight

11. Marketed Biosimilar Insulin Clinical Insight by Company, Indication & Phase

12. Biosimilar Insulin Future Targeted Market

13. Global Biosimilar Insulin Market Dynamics

14. Future Implications of Biosimilar Insulin

15. Competitive Landscape

- Biocon

- Biogenomics

- Eli Lilly

- Gan&Lee Pharmaceuticals

- Geropharm

- Julphar Gulf Pharmaceutical Industries

- Paras Biopharmaceuticals

- Samsung (News - Alert) Bioepis

- Sedico

- Wockhardt

For more information about this report visit http://www.researchandmarkets.com/research/8fqvsg/global_biosimilar

View source version on businesswire.com: http://www.businesswire.com/news/home/20170227006085/en/

[ Back To TMCnet.com's Homepage ]